Serum levels of macrophage colony-stimulating factor-1 in cervical human papillomavirus infection and intraepithelial neoplasia

R. A. Adam, I. R. Horowitz, Rajeshwar R Tekmal

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: Our goal was determine the correlation between serum colony stimulating factor-1 levels, cervical human papillomavirus infection, and dysplasia. STUDY DESIGN: serum samples were obtained from control subjects from the United States and from a group of Panamanian women. Members of the latter group fell into 3 categories: those who serve as Panamanian control subjects and who test negative for human papillomavirus (n = 10); those who are high risk by history and test positive for human papillomavirus types 16/18 and 30s (n = 10); and those with the same high-risk history with biopsy-proven cervical intraepithelial neoplasia (n = 8). Serum colony- stimulating factor-1 levels were determined using enzyme-linked immunosorbent assay. Data were analyzed with the Student-Newman-Keuls and t tests. RESULTS: Mean serum colony-stimulating factor-1 levels of patients with a positive test result for human papillomavirus (1166 ± 949 pg/mL) and cervical intraepithelial neoplasia (1295 ± 314 pg/mL) were higher than those of control subjects from the United States (584 ± 237 pg/mL) and those of Panamanian control subjects (520 ± 229 pg/mL). Statistical analysis revealed the concentration of colony-stimulating factor in patients with positive test results for human papillomavirus or cervical intraepithelial neoplasia were significantly higher than in control groups. In addition, combining patients with human papillomavirus with those who have cervical intraepithelial neoplasia results in a group that has significantly higher colony-stimulating factor levels compared with control subjects. CONCLUSIONS: Both high-grade cervical dysplasia and high-risk human papillomavirus infection are associated with higher mean serum colony-stimulating factor levels, suggesting a possible role for colony-stimulating factor-1 in cervical neoplasia. Further studies are needed to understand the mechanism of colony- stimulating factor activation in human papillomavirus infection. This may assist in designing therapeutic approaches for the management of this disease.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume180
Issue number1 I
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor
Papillomavirus Infections
Colony-Stimulating Factors
Cervical Intraepithelial Neoplasia
Serum
Neoplasms
Uterine Cervical Dysplasia
Human papillomavirus 18
Human papillomavirus 16
Disease Management
History
Enzyme-Linked Immunosorbent Assay
Students
Biopsy
Control Groups

Keywords

  • Cervical neoplasia
  • Colony-stimulating factor-1
  • CSF-1
  • Human papillomavirus
  • Serum levels

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

@article{f23ce079134340aea98101345c64c90c,
title = "Serum levels of macrophage colony-stimulating factor-1 in cervical human papillomavirus infection and intraepithelial neoplasia",
abstract = "OBJECTIVE: Our goal was determine the correlation between serum colony stimulating factor-1 levels, cervical human papillomavirus infection, and dysplasia. STUDY DESIGN: serum samples were obtained from control subjects from the United States and from a group of Panamanian women. Members of the latter group fell into 3 categories: those who serve as Panamanian control subjects and who test negative for human papillomavirus (n = 10); those who are high risk by history and test positive for human papillomavirus types 16/18 and 30s (n = 10); and those with the same high-risk history with biopsy-proven cervical intraepithelial neoplasia (n = 8). Serum colony- stimulating factor-1 levels were determined using enzyme-linked immunosorbent assay. Data were analyzed with the Student-Newman-Keuls and t tests. RESULTS: Mean serum colony-stimulating factor-1 levels of patients with a positive test result for human papillomavirus (1166 ± 949 pg/mL) and cervical intraepithelial neoplasia (1295 ± 314 pg/mL) were higher than those of control subjects from the United States (584 ± 237 pg/mL) and those of Panamanian control subjects (520 ± 229 pg/mL). Statistical analysis revealed the concentration of colony-stimulating factor in patients with positive test results for human papillomavirus or cervical intraepithelial neoplasia were significantly higher than in control groups. In addition, combining patients with human papillomavirus with those who have cervical intraepithelial neoplasia results in a group that has significantly higher colony-stimulating factor levels compared with control subjects. CONCLUSIONS: Both high-grade cervical dysplasia and high-risk human papillomavirus infection are associated with higher mean serum colony-stimulating factor levels, suggesting a possible role for colony-stimulating factor-1 in cervical neoplasia. Further studies are needed to understand the mechanism of colony- stimulating factor activation in human papillomavirus infection. This may assist in designing therapeutic approaches for the management of this disease.",
keywords = "Cervical neoplasia, Colony-stimulating factor-1, CSF-1, Human papillomavirus, Serum levels",
author = "Adam, {R. A.} and Horowitz, {I. R.} and Tekmal, {Rajeshwar R}",
year = "1999",
doi = "10.1016/S0002-9378(99)70144-4",
language = "English (US)",
volume = "180",
pages = "28--32",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1 I",

}

TY - JOUR

T1 - Serum levels of macrophage colony-stimulating factor-1 in cervical human papillomavirus infection and intraepithelial neoplasia

AU - Adam, R. A.

AU - Horowitz, I. R.

AU - Tekmal, Rajeshwar R

PY - 1999

Y1 - 1999

N2 - OBJECTIVE: Our goal was determine the correlation between serum colony stimulating factor-1 levels, cervical human papillomavirus infection, and dysplasia. STUDY DESIGN: serum samples were obtained from control subjects from the United States and from a group of Panamanian women. Members of the latter group fell into 3 categories: those who serve as Panamanian control subjects and who test negative for human papillomavirus (n = 10); those who are high risk by history and test positive for human papillomavirus types 16/18 and 30s (n = 10); and those with the same high-risk history with biopsy-proven cervical intraepithelial neoplasia (n = 8). Serum colony- stimulating factor-1 levels were determined using enzyme-linked immunosorbent assay. Data were analyzed with the Student-Newman-Keuls and t tests. RESULTS: Mean serum colony-stimulating factor-1 levels of patients with a positive test result for human papillomavirus (1166 ± 949 pg/mL) and cervical intraepithelial neoplasia (1295 ± 314 pg/mL) were higher than those of control subjects from the United States (584 ± 237 pg/mL) and those of Panamanian control subjects (520 ± 229 pg/mL). Statistical analysis revealed the concentration of colony-stimulating factor in patients with positive test results for human papillomavirus or cervical intraepithelial neoplasia were significantly higher than in control groups. In addition, combining patients with human papillomavirus with those who have cervical intraepithelial neoplasia results in a group that has significantly higher colony-stimulating factor levels compared with control subjects. CONCLUSIONS: Both high-grade cervical dysplasia and high-risk human papillomavirus infection are associated with higher mean serum colony-stimulating factor levels, suggesting a possible role for colony-stimulating factor-1 in cervical neoplasia. Further studies are needed to understand the mechanism of colony- stimulating factor activation in human papillomavirus infection. This may assist in designing therapeutic approaches for the management of this disease.

AB - OBJECTIVE: Our goal was determine the correlation between serum colony stimulating factor-1 levels, cervical human papillomavirus infection, and dysplasia. STUDY DESIGN: serum samples were obtained from control subjects from the United States and from a group of Panamanian women. Members of the latter group fell into 3 categories: those who serve as Panamanian control subjects and who test negative for human papillomavirus (n = 10); those who are high risk by history and test positive for human papillomavirus types 16/18 and 30s (n = 10); and those with the same high-risk history with biopsy-proven cervical intraepithelial neoplasia (n = 8). Serum colony- stimulating factor-1 levels were determined using enzyme-linked immunosorbent assay. Data were analyzed with the Student-Newman-Keuls and t tests. RESULTS: Mean serum colony-stimulating factor-1 levels of patients with a positive test result for human papillomavirus (1166 ± 949 pg/mL) and cervical intraepithelial neoplasia (1295 ± 314 pg/mL) were higher than those of control subjects from the United States (584 ± 237 pg/mL) and those of Panamanian control subjects (520 ± 229 pg/mL). Statistical analysis revealed the concentration of colony-stimulating factor in patients with positive test results for human papillomavirus or cervical intraepithelial neoplasia were significantly higher than in control groups. In addition, combining patients with human papillomavirus with those who have cervical intraepithelial neoplasia results in a group that has significantly higher colony-stimulating factor levels compared with control subjects. CONCLUSIONS: Both high-grade cervical dysplasia and high-risk human papillomavirus infection are associated with higher mean serum colony-stimulating factor levels, suggesting a possible role for colony-stimulating factor-1 in cervical neoplasia. Further studies are needed to understand the mechanism of colony- stimulating factor activation in human papillomavirus infection. This may assist in designing therapeutic approaches for the management of this disease.

KW - Cervical neoplasia

KW - Colony-stimulating factor-1

KW - CSF-1

KW - Human papillomavirus

KW - Serum levels

UR - http://www.scopus.com/inward/record.url?scp=0032986349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032986349&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(99)70144-4

DO - 10.1016/S0002-9378(99)70144-4

M3 - Article

C2 - 9914573

AN - SCOPUS:0032986349

VL - 180

SP - 28

EP - 32

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1 I

ER -